In my opinion, just because thereâs a Buy or Sell rating doesnât necessarily mean anyone should âdefinitelyâ buy or sell that stock. If anything it gives you a glimpse of sentiment. Can analyst actions impact stock prices? Yes and weâve seen that in real-time over the last few weeks. But after the dust settles, itâs up to traders themselves to digest the information and fold it in with the rest of their analysis. Keeping this in mind, here are a few penny stocks with Buy ratings that also have hefty price targets. Will these find their way on your watch list before next year?Penny Stocks To Buy [Lake Street Capital]: SeaChange International Inc.
Zydus to initiate Ph III trials of COVID-19 vaccine candidate
Zydus to initiate Ph III trials of COVID-19 vaccine candidate
01 January 2021 | News The Phase II study of the vaccine ZyCoV-D had been conducted in over 1000 healthy adult volunteers
Source credit: Shutterstock
Zydus Cadila has announced that its plasmid DNA vaccine to prevent COVID-19, ZyCoV-D was found to be safe, well tolerated and immunogenic in the Phase I/II clinical trials. The company is now planning to initiate Phase III clinical trial in around 30,000 volunteers upon receiving necessary approvals.
The Phase II study of the vaccine ZyCoV-D had been conducted in over 1000 healthy adult volunteers as part of the adaptive Phase I/II dose escalation, multi-centric, randomised, double-blind placebo controlled study. The vaccine was found to be safe and immunogenic.
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a AMBITION Clinical Trial for Treatment of Advanced NASH saltlakecitysun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from saltlakecitysun.com Daily Mail and Mail on Sunday newspapers.
Hepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a AMBITION Clinical Trial for Treatment of Advanced NASH
- DSMB Recommended the AMBITION Study Continue with Final Dosing Cohort -
- Final Cohort Expected to be Completed in Early 2021 -
EDISON, NJ / ACCESSWIRE / December 29, 2020
/ Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA, Hepion ), a clinical stage biopharmaceutical company focused on Artificial Intelligence ( AI )-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ( NASH ) and liver disease, today announced that an independent Data Safety Monitoring Board ( DSMB ) has approved the continuation of the Company s Phase 2a AMBITION clinical trial.
Column: Delivering safe and effective vaccines duncanbanner.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from duncanbanner.com Daily Mail and Mail on Sunday newspapers.